Gene therapy and the adeno‐associated virus in the treatment of genetic and acquired ophthalmic diseases in humans: Trials, future directions and safety considerations

Abstract excerpt

Voretigene neparvovec-rzyl was recently approved for the treatment of Leber congenital amaurosis, and the use of gene therapy for eye disease is attracting even greater interest. The eye has immune privileged status, is easily accessible, requires a reduced dosage of therapy due to its size and is highly compartmentalized, significantly reducing systemic spread. Adeno-associated virus (AAV), with its low...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Retinal Development and Disorders
• Share to Retinal Diseases and Treatments
• Share to Virus-based gene therapy research